ClinicalTrials.gg
CompletedNCT00433836Updated May 19, 2011Results posted

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

A Phase 3 interventional study of Valsartan and Enalapril in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in 11 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2011-05-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
56th of 139
300 · median 198
Started
2007
with 11 others
Phase 3
53 of 140
none open now
Registered
74th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 56th largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 74th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this 12-week active controlled trial is to evaluate the safety and efficacy of valsartan 80/160/320 mg (weight stratified) compared with enalapril 10/20/40 mg (weight stratified) on sitting systolic blood pressure (SSBP) in 6 - 17 year old children with hypertension (SSBP ≥ 95th percentile for age gender and height).

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Children
  • pediatrics
  • High Blood Pressure
  • Hypertension
  • Valsartan
  • enalapril
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ages 6-17, with a documented history of hypertension
  • Must be able to swallow a pill
  • Must be ≥ 18 kg or ≤160 kg
  • MSSBP (mean of 3 measurements) must be ≥ 95th percentile, for age, gender and height, at Visit 2 (randomization), by office blood pressure measurement
  • Patients who are eligible and able to participate in the study and whose parent(s)/guardian(s) consent in writing (written ) to their doing so after the purpose and nature of the investigation has been clearly explained to them. (An assent will be required for some patients depending upon their age and local requirements regarding assents)

Exclusion criteria

Exclusion Criteria:

  • Renal artery stenosis
  • Current diagnosis of heart failure ( Class II-IV).
  • MSSBP ≥ 25% above the 95th percentile
  • Second or third degree heart block without a pacemaker.
  • Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.
  • valvular heart disease.
  • Patient that demonstrates clinically significant abnormalities other than those associated with left ventricular hypertrophy.
  • Previous solid organ transplantation except renal, liver or heart transplantation. Renal, liver or heart transplant must have occurred at least 6 months prior to enrollment. Patient must be on stable doses of therapy for 3 months and deemed clinically stable by the investigator.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Valsartan 80 mg

    Drug: Valsartan

  • Experimental
    Valsartan 160 mg

    Drug: Valsartan

  • Experimental
    Valsartan 320 mg

    Drug: Valsartan

  • Active comparator
    Enalapril 10 mg

    Drug: Enalapril

  • Active comparator
    Enalapril 20 mg

    Drug: Enalapril

  • Active comparator
    Enalapril 40 mg

    Drug: Enalapril

Interventions

  • Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.

  • Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)

    Mean sitting systolic blood pressure (MSSBP) change after 12 weeks of treatment measured by office blood pressure measurement.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)

    The change from baseline in mean sitting diastolic blood pressure (MSDBP) after 12 weeks of treatment as measured by office blood pressure.

    Time frame: Baseline and Week 12

  2. Decrease in MSSBP to < 95th Percentile for Age, Gender and Height

    The percentage of children whose MSSBP decreased to \<95th percentile for age, gender, and height on valsartan vs. enalapril monotherapy at week 12.

    Time frame: at week 12

  3. Change From Baseline in Mean Ambulatory Systolic Blood Pressure (ASBP) and Mean Ambulatory Diastolic Blood Pressure (ADBP) Over 24 Hours in Subset of Patients

    The effect of valsartan and enalapril between baseline and visit 6 on 24-hour mean ambulatory systolic and diastolic blood pressure (ASBP, ADBP) in a subset of patients.

    Time frame: Baseline and Week 8

07

Results

Posted May 19, 2011

Participant flow

Participant flow — Overall Study
MilestoneValsartanEnalapril
Started151149
Completed138143
Not completed136
Withdrew: Adverse event70
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject21
Withdrew: Unsatisfactory therapeutic effect11
Withdrew: Protocol violation02
Withdrew: Condition no longer requires study drug01
Withdrew: Abnormal laboratory values01

Outcome measures

PrimaryChange From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)

Mean sitting systolic blood pressure (MSSBP) change after 12 weeks of treatment measured by office blood pressure measurement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mm Hg
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)
mm HgValsartanEnalapril
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)-15.4 ± 1.29-14.1 ± 1.28
Statistical analysis
  • Valsartan vs Enalapril · ANOVA · Mean difference (final values): -1.3 · 95% CI -3.80 to 1.17
SecondaryChange From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)

The change from baseline in mean sitting diastolic blood pressure (MSDBP) after 12 weeks of treatment as measured by office blood pressure.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mm Hg
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
mm HgValsartanEnalapril
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)-9.4 ± 0.94-8.5 ± 0.95
SecondaryDecrease in MSSBP to < 95th Percentile for Age, Gender and Height

The percentage of children whose MSSBP decreased to \<95th percentile for age, gender, and height on valsartan vs. enalapril monotherapy at week 12.

Time frame:
at week 12
Reported as:
Number · Percentage of participants
Decrease in MSSBP to < 95th Percentile for Age, Gender and Height
Percentage of participantsValsartanEnalapril
Decrease in MSSBP to < 95th Percentile for Age, Gender and Height66.970.3
SecondaryChange From Baseline in Mean Ambulatory Systolic Blood Pressure (ASBP) and Mean Ambulatory Diastolic Blood Pressure (ADBP) Over 24 Hours in Subset of Patients

The effect of valsartan and enalapril between baseline and visit 6 on 24-hour mean ambulatory systolic and diastolic blood pressure (ASBP, ADBP) in a subset of patients.

Time frame:
Baseline and Week 8
Reported as:
Mean · mm Hg
Change From Baseline in Mean Ambulatory Systolic Blood Pressure (ASBP) and Mean Ambulatory Diastolic Blood Pressure (ADBP) Over 24 Hours in Subset of Patients
mm HgValsartanEnalapril
ASBP-9.8 ± 6.75-6.8 ± 7.41
ADBP-9.3 ± 6.27-5.5 ± 5.73

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan—3/151 (2%)42/151 (27.8%)
Enalapril—2/148 (1.4%)52/148 (35.1%)
Most frequent serious events
Most frequent serious events
EventValsartanEnalapril
Avulsion fractureInjury, poisoning and procedural complications0/1511/148
Renal injuryInjury, poisoning and procedural complications0/1511/148
DehydrationMetabolism and nutrition disorders1/1510/148
HyperkalaemiaMetabolism and nutrition disorders1/1510/148
Brain injuryNervous system disorders1/1510/148
Most frequent other events
Most frequent other events
EventValsartanEnalapril
HeadacheNervous system disorders18/15128/148
PharyngitisInfections and infestations6/15111/148
CoughRespiratory, thoracic and mediastinal disorders9/15110/148
NasopharyngitisInfections and infestations10/1518/148
Upper respiratory tract infectionInfections and infestations10/1517/148

Baseline characteristics

Age Continuous
Age Continuous(years)ValsartanEnalaprilTotal
Mean12.7 ± 2.9313.0 ± 2.9412.9 ± 2.93
Sex: Female, Male
Sex: Female, Male(Participants)ValsartanEnalaprilTotal
Female6544109
Male86105191
08

Study locations

11 sites
  • Sites in USA
    East Hanover, New Jersey 07936, United States
  • Sites in Belgium
    Sites in Belgium, Belgium
  • Sites in France
    Sites in France, France
  • Sites in Germany
    Sites in Germany, Germany
  • Sites in Hungary
    Hungary, Hungary
  • Sites in India
    Sites in India, India
  • Sites in Italy
    Sites in Italy, Italy
  • Sites in Poland
    Poland, Poland
  • Sites in Slovakia
    Slovakia, Slovakia
  • Sites in Sweden
    Sites in Sweden, 00000, Sweden
  • Sites in Turkey
    Turkey, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2007
First posted
Feb 12, 2007
Start
Jan 2007
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
May 19, 2011
Last update
May 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00433836
First posted
Feb 12, 2007
Start date
Jan 2007
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
May 19, 2011
Last update
May 19, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion